Genetic polymorphisms of pharmacogenomic very important pharmacogenes variants in Chinese Lisu population
10.3867/j.issn.1000-3002.2021.10.025
- Author:
Hong-Yan LU
1
,
2
;
Yu-Liang WANG
;
Zhan-Hao ZHANG
;
Shi-Shi XING
;
Dan-Dan LI
;
Li WANG
;
Tian-Bo JIN
Author Information
1. Key Laboratory of Molecular Mechanism and Intervention Research for Plateau Diseases of Tibet Autonomous Region,School of Medicine,Xizang Minzu University,Xianyang 712082,China
2. Engineering Research Center of Tibetan Medicine Detection Technology,Ministry of Education,Xizang Minzu University,Xianyang 712082,China
- Keywords:
very important pharmacogenes variants;
Lisu population;
pharmacogenomics;
racial difference
- From:
Chinese Journal of Pharmacology and Toxicology
2021;35(10):735-735
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE The specificity of drug therapy in individuals and races has promoted the development and improvement of pharmacogenomics and precision medicine. While there is a few cognition on the minorities in China, especially in Lisu nationality from the Yunnan province. Therefore, we performed the research to improve the role of pharmacogenomics in the Lisu population from the Yunnan province of China. METHODS 54 variants of very important pharmacogenes selected from the PharmGKB database were genotyped in 199 unrelated and healthy Lisu adults from the Yunnan province of China, and then, genotyping data wtihχ2 test were analyzed. RESULTS We compared our data with those of other 26 populations from the 1000 Genomes Project, and acquired that the Lisu ethnicity is similar with the CDX (Chinese Dai in Xishuangbanna, China) and CHS (Southern Han Chinese, China). Furthermore, rs776746 (CYP3A5), rs1805123 (KCNH2), rs4291 (ACE), rs1051298 (SLC19A1) and rs1065852 (CYP2D6) were deemed as the most varying loci. The MAF of"G"at rs1805123 (KCNH2) in the Lisu population was the largest with the value of 51.0％. CONCLUSION There are significant differences in single nucleotide polymorphism loci, supplementing the phar?macogenomic information of the Lisu population in Yunnan province, China, and can provide a theoretical basis for indi?vidualized medication in the future.
